Literature DB >> 6458585

Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets.

T Hercend, J Ritz, S F Schlossman, E L Reinherz.   

Abstract

In the present study, the expression of three surface molecules T9, T10, and Ia, which are found on activated T lymphocytes, was examined utilizing monoclonal antibodies and indirect immunofluorescence. These antigens were shown to appear on T lymphocytes in a defined temporal sequence which was dependent on the specific triggering stimulus. Moreover, when T cells were fractionated into individual subsets of T4+ inducer and T8+ cytotoxic/suppressor lymphocytes, the expression of all three molecules was restricted to the T4+ subset following soluble antigen stimulation. By contrast, both subsets expressed these surface determinants following mitogen or alloantigen stimulation. The above results suggest that there may be successive stages in the T cell activation process associated with the appearance of unique cell surface antigens and further support the view that various triggering stimuli activate T cell populations differently.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458585     DOI: 10.1016/0198-8859(81)90021-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  36 in total

Review 1.  Immunoregulatory T cell subsets and T cell activation in rheumatoid arthritis. A need for analysis on the clonal and molecular level.

Authors:  A Quayle; J Kjeldsen-Kragh; O Førre; K Waalen; M Sioud; C Kalvenes; J B Natvig
Journal:  Springer Semin Immunopathol       Date:  1989

2.  Decreased expression of CD7 occurs in rheumatoid arthritis.

Authors:  A I Lazarovits; J Karsh
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

3.  Elevated numbers of peripheral T cells in inflammatory bowel diseases displaying T9 antigen and Fc alpha receptors.

Authors:  A Raedler; S Fraenkel; G Klose; H G Thiele
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

4.  Preferential loss of Leu 8-, CD45R, HLA-DR+ CD8 cell subsets during in vitro culture of mononuclear cells from human immunodeficiency virus type I (HIV)-seropositive former blood donors.

Authors:  H E Prince; C D Czaplicki
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

5.  Immature T lymphocytes after injury characterized by morphology and phenotypic markers.

Authors:  J J Wood; J B O'Mahony; M L Rodrick; J A Mannick
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

6.  IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Authors:  G Ferrari; K King; K Rathbun; C A Place; M V Packard; J A Bartlett; D P Bolognesi; K J Weinhold
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

7.  The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. II. The localization of mononuclear cells as detected by monoclonal antibodies directed against T-lymphocyte subsets and natural killer cells.

Authors:  B Koch; P Locher; G R Burmester; W Mohr; J R Kalden
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

8.  Changes in rectal leucocytes after allogeneic bone marrow transplantation.

Authors:  S A Dilly; J P Sloane
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

9.  Characterization of early lymphoid precursor cells in the human fetus using monoclonal antibodies and anti-terminal deoxynucleotidyl transferase.

Authors:  G E Asma; R L van den Bergh; J M Vossen
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

10.  Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection.

Authors:  G Vanham; L Kestens; G Penne; C Goilav; P Gigase; R Colebunders; M Vandenbruaene; J Goeman; G van der Groen; J L Ceuppens
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.